DPI developer Chance Pharmaceuticals announced the completion of a financing round with participation from Heda Health Fund and Qihang Venture Capital, with proceeds intended to support Phase 3 trials of CXG87 inhaled dry powder budesonide / formoterol as well as development of some additional DPI formulations. The company did not specify the amount raised. Chance … [Read more...] about Chance Pharma announces funding to support Phase 3 trial of CXG87 budesonide / formoterol DPI
News
Polyrizon announces development of intranasal naloxone and agreement to develop intranasal formulation of a psychedelic therapy
Israeli biotech Polyrizon announced that it is beginning preclinical development of an intranasal naloxone formulation based on the company's Trap and Target mucoadhesive technology. The company said that Fabio Sonvico of the University of Parma, who is a member of Polyrizon's scientific advisory board, will conduct the studies. Polyrizon CEO Tomer Izraeli … [Read more...] about Polyrizon announces development of intranasal naloxone and agreement to develop intranasal formulation of a psychedelic therapy
Armata announces $10 million loan from Innoviva to fund development of candidates including AP-PA02 inhaled phage therapy
Armata Pharmaceuticals announced details of an additional secured credit agreement with Innoviva Strategic Opportunities, the company's largest shareholder. Armata said that it will pay interest at a 14% annual rate on the $10 million loan which matures on March 12, 2026. According to the announcement, the funds will be used for continued development of candidates … [Read more...] about Armata announces $10 million loan from Innoviva to fund development of candidates including AP-PA02 inhaled phage therapy
Emergent BioSolutions and Rocketvax form joint venture for development of intranasal vaccine candidates
Emergent BioSolutions and Swiss biotech Rocketvax have announced that Emergent will make a strategic investment in Rocketvax parent company Swiss Rockets and will take over manufacturing and commercialization activities for 4 of Rocketvax's intranasal vaccine candidates. Rocketvax's pipeline includes live attenuated intranasal vaccines for melanoma and multiple … [Read more...] about Emergent BioSolutions and Rocketvax form joint venture for development of intranasal vaccine candidates
Xlear says US DOJ has requested dismissal of FTC case against company for unsupported claims about its OTC nasal spray
According to Xlear, the US Department of Justice has asked a US District Court judge to dismiss a suit filed by the US Federal Trade Commission in 2021 accusing the company of violating the COVID-19 Consumer Protection Act by claiming that its saline nasal spray with xylitol could prevent and treat COVID-19. The case (2:21-cv-00640-RJS) was brought in the US District … [Read more...] about Xlear says US DOJ has requested dismissal of FTC case against company for unsupported claims about its OTC nasal spray
McMaster University initiates the AeroVax Phase 2 trial of its inhaled COVID-19 vaccine
McMaster University has announced the initiation of the AeroVax Phase 2 trial of its ChAd-triCoV/Mac inhaled vaccine against SARS-CoV-2. According to McMaster, the Canadian Institutes of Health Research has provided $8 million to support the study, which will be led by researchers from the university's Michael G. DeGroote Institute for Infectious Disease Research. … [Read more...] about McMaster University initiates the AeroVax Phase 2 trial of its inhaled COVID-19 vaccine
Oragenics submits application for Phase 2 trial of ONP-002 intranasal neurosteroid powder for TBI
Oragenics announced that it has submitted an Investigator’s Brochure application to Australian authorities seeking the go-ahead for a Phase 2 trial of ONP-002, a dry powder intranasal neurosteroid, for the treatment of mild traumatic brain injury. In 2023, Oragenics acquired ONP-002 from Odyssey Health, which had announced Phase 1 results the previous year. In August … [Read more...] about Oragenics submits application for Phase 2 trial of ONP-002 intranasal neurosteroid powder for TBI
Altamira gets US patent covering Bentrio bentonite nasal spray formulation
Altamira Therapeutics said that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent covering the formulation of Bentrio bentonite-based nasal spray. Bentrio received 510(k) clearance in the US in June 2022. In 2023, the company sold a 51% stake in its subsidiary Altamira Medica, which developed Bentrio for the prevention … [Read more...] about Altamira gets US patent covering Bentrio bentonite nasal spray formulation
Tiziana submits IND for Phase 2 trial of intranasal foralumab in ALS
Tiziana Life Sciences announced that it has submitted an IND to the FDA seeking approval for a Phase 2 trial of intranasal foralumab in patients with amyotrophic lateral sclerosis. In November 2024, the company announced that it had received a grant from the ALS Association to fund a trial in patients with ALS. According to the company, the planned Phase 2 study would … [Read more...] about Tiziana submits IND for Phase 2 trial of intranasal foralumab in ALS
Iconovo gets SEK 670,000 Innowwide grant to explore selling its DPIs and services in the Japanese market
According to DPI developer Iconovo, the company has received a grant worth SEK 670,000 from the EU's Innowwide initiative, which encourages small and medium-sized EU companies to enter international markets. The grant will fund a market study this year that will evaluate opportunities for Iconovo to partner with Japanese companies to sell its products and services in … [Read more...] about Iconovo gets SEK 670,000 Innowwide grant to explore selling its DPIs and services in the Japanese market